Ponatinib treatment in chronic myeloid leukemia cell lines targets aurora kinase A/FOXM1 axis

Hematol Oncol. 2020 Apr;38(2):201-203. doi: 10.1002/hon.2703. Epub 2020 Jan 28.
No abstract available

Publication types

  • Letter

MeSH terms

  • Apoptosis / drug effects*
  • Aurora Kinase A / genetics
  • Aurora Kinase A / metabolism*
  • Cell Proliferation / drug effects
  • Drug Resistance, Neoplasm*
  • Forkhead Box Protein M1 / genetics
  • Forkhead Box Protein M1 / metabolism*
  • Gene Expression Regulation, Neoplastic / drug effects*
  • Humans
  • Imidazoles / pharmacology*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / metabolism
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology*
  • Protein Kinase Inhibitors / pharmacology
  • Pyridazines / pharmacology*
  • Tumor Cells, Cultured

Substances

  • FOXM1 protein, human
  • Forkhead Box Protein M1
  • Imidazoles
  • Protein Kinase Inhibitors
  • Pyridazines
  • ponatinib
  • AURKA protein, human
  • Aurora Kinase A